Clofazimine-induced enteropathy in treatment-resistant nodular vasculitis

The Australasian Journal of Dermatology
Violet KieuRob Kelly

Abstract

We report a chronic case of nodular vasculitis that responded to oral clofazimine 300 mg daily. The condition had previously responded to moderate dose oral prednisolone, 50 mg daily, but would recur with weaning. Multiple corticosteroid-sparing agents were trialled, however these were either ineffective or poorly tolerated. The introduction of clofazimine enabled prednisolone dose reduction, not achieved with other agents, to 22.5 mg daily, and was associated with complete suppression of disease activity. Unfortunately the patient developed a clofazimine-induced enteropathy and the treatment was ceased after almost 2 years of therapy. Cessation of clofazimine was associated with a flare of the condition. Clofazimine should be considered as a corticosteroid-sparing agent in resistant cases of nodular vasculitis. Clinicians should be aware of clofazimine-induced enteropathy as a potentially serious complication of the therapy.

References

Feb 1, 1995·Journal of the American Academy of Dermatology·J L Arbiser, S L Moschella
Jan 1, 1993·Pathology·P Y Chong, T K Ti
Jun 26, 1999·The Journal of Antimicrobial Chemotherapy·V M ReddyP R Gangadharam
Jan 13, 2000·The American Journal of Surgical Pathology·S SukpanichnantK Thakerngpol
Mar 25, 2005·The British Journal of Dermatology·F AbuzahraJ Frank
Sep 17, 2008·Dermatologic Clinics·José M Mascaró, Eulalia Baselga

❮ Previous
Next ❯

Citations

Nov 2, 2016·Open Forum Infectious Diseases·Winnie SzetoMichele I Morris

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.